

Robert B Jenkins

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4334772/robert-b-jenkins-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

166
papers

12,041
citations

53
h-index

108
g-index

172
ext. papers

14,153
ext. citations

6.9
avg, IF

5.56
L-index

#	Paper	IF	Citations
166	Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. <i>New England Journal of Medicine</i> , 2015 , 372, 2499-508	59.2	1181
165	Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. <i>Journal of Clinical Oncology</i> , 2000 , 18, 636-45	2.2	899
164	Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. <i>Journal of Clinical Oncology</i> , 2013 , 31, 337-43	2.2	767
163	A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. <i>Cancer Research</i> , 2006 , 66, 9852-61	10.1	563
162	Novel mutations of the MET proto-oncogene in papillary renal carcinomas. <i>Oncogene</i> , 1999 , 18, 2343-50	9.2	438
161	The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. <i>Nature Communications</i> , 2014 , 5, 5383	17.4	432
160	Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. <i>Nature Genetics</i> , 2009 , 41, 905-8	36.3	396
159	cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". <i>Acta Neuropathologica</i> , 2018 , 136, 805-810	14.3	367
158	Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. <i>Cancer Research</i> , 1997 , 57, 524-31	10.1	313
157	Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. <i>Oncogene</i> , 1999 , 18, 4144-52	9.2	311
156	Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. <i>Journal of Clinical Oncology</i> , 2014 , 32, 783-90	2.2	280
155	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. <i>Lancet, The</i> , 2017 , 390, 1645-1653	40	225
154	A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. <i>Nature Genetics</i> , 2011 , 43, 1098-103	36.3	203
153	RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SCHLAP1. <i>Lancet Oncology, The</i> , 2014 , 15, 1469-1480	21.7	192
152	Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. <i>Acta Neuropathologica</i> , 2017 , 133, 1001-1016	14.3	185
151	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. <i>Acta Neuropathologica</i> , 2020 , 139, 603-608	14.3	170
150	Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. <i>Nature Genetics</i> , 2017 , 49, 789-794	36.3	163

149	Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma. <i>Cancer</i> , 1998 , 83, 1995-2002	6.4	156
148	Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas. <i>Genes Chromosomes and Cancer</i> , 1992 , 5, 348-56	5	156
147	Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 701-8	2.2	142
146	Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. <i>Nature Genetics</i> , 2014 , 46, 731-5	36.3	141
145	Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. <i>European Urology</i> , 2015 , 67, 326-33	10.2	135
144	Radiogenomics to characterize regional genetic heterogeneity in glioblastoma. <i>Neuro-Oncology</i> , 2017 , 19, 128-137	1	121
143	TP53 gene mutations and 17p deletions in human astrocytomas. <i>Genes Chromosomes and Cancer</i> , 1991 , 3, 323-31	5	117
142	A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. <i>Nature Genetics</i> , 2012 , 44, 1122-5	36.3	108
141	Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. <i>Brain Pathology</i> , 2008 , 18, 360-9	6	107
140	A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2014 , 17, 64-9	6.2	102
139	Correlation of cytogenetic analysis and loss of heterozygosity studies in human diffuse astrocytomas and mixed oligo-astrocytomas. <i>Genes Chromosomes and Cancer</i> , 1992 , 5, 357-74	5	102
138	Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. <i>European Urology</i> , 2015 , 68, 555-67	10.2	100
137	Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. <i>Modern Pathology</i> , 2001 , 14, 842-53	9.8	97
136	Fluorescence in situ hybridization: a sensitive method for trisomy 8 detection in bone marrow specimens. <i>Blood</i> , 1992 , 79, 3307-15	2.2	91
135	Small cell architecture--a histological equivalent of EGFR amplification in glioblastoma multiforme?. <i>Journal of Neuropathology and Experimental Neurology</i> , 2001 , 60, 1099-104	3.1	87
134	Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2000 , 27, 95-103	5	87
133	IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. <i>Oncotarget</i> , 2015 , 6, 30295-3053	3.3	86
132	Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas. <i>Genes Chromosomes and Cancer</i> , 2005 , 42, 68-77	5	80

131	MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. <i>Cancer Research</i> , 2017 , 77, 1021-1034	10.1	74
130	Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0M0 prostate cancer. <i>Genes Chromosomes and Cancer</i> , 1998 , 21, 131-143	5	74
129	Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers. <i>Cancer</i> , 1994 , 74, 920-7	6.4	74
128	ARV7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. <i>Cancer Cell</i> , 2019 , 35, 401-413.e6	24.3	74
127	Multi-Parametric MRI and Texture Analysis to Visualize Spatial Histologic Heterogeneity and Tumor Extent in Glioblastoma. <i>PLoS ONE</i> , 2015 , 10, e0141506	3.7	73
126	Management of diffuse low-grade gliomas in adults - use of molecular diagnostics. <i>Nature Reviews Neurology</i> , 2017 , 13, 340-351	15	72
125	Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. <i>Genes Chromosomes and Cancer</i> , 2000 , 29, 16-25	5	70
124	Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	66
123	Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 282-90	4	66
122	FRA7G extends over a broad region: coincidence of human endogenous retroviral sequences (HERV-H) and small polydispersed circular DNAs (spcDNA) and fragile sites. <i>Oncogene</i> , 1998 , 16, 2311-9	9.2	66
121	Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. <i>Oncotarget</i> , 2015 , 6, 42468-77	3.3	66
120	Distinct germ line polymorphisms underlie glioma morphologic heterogeneity. <i>Cancer Genetics</i> , 2011 , 204, 13-8	2.3	62
119	TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. <i>Clinical Cancer Research</i> , 2017 , 23, 7072-7083	12.9	61
118	Fish mapping of YAC clones at human chromosomal band 7q31.2: identification of YACS spanning FRA7G within the common region of LOH in breast and prostate cancer. <i>Genes Chromosomes and Cancer</i> , 1998 , 21, 152-9	5	60
117	A molecular cytogenetic analysis of 7q31 in prostate cancer. <i>Cancer Research</i> , 1998 , 58, 759-66	10.1	59
116	SVAtools for junction detection of genome-wide chromosomal rearrangements by mate-pair sequencing (MPseq). <i>Cancer Genetics</i> , 2018 , 221, 1-18	2.3	57
115	Cytogenetic analysis of aggressive meningiomas: possible diagnostic and prognostic implications. <i>Cancer</i> , 1996 , 77, 2567-73	6.4	54
114	Telomere maintenance and the etiology of adult glioma. <i>Neuro-Oncology</i> , 2015 , 17, 1445-52	1	53

113	Loss of expression of the DRR 1 gene at chromosomal segment 3p21.1 in renal cell carcinoma. <i>Genes Chromosomes and Cancer</i> , 2000 , 27, 1-10	5	48
112	Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. <i>Oncogene</i> , 2017 , 36, 3417-3427	9.2	47
111	PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance. <i>Modern Pathology</i> , 2016 , 29, 764-71	9.8	47
110	Chromosomal Anomalies in Stage D1 Prostate Adenocarcinoma Primary Tumors and Lymph Node Metastases Detected by Fluorescence in Situ Hybridization. <i>Journal of Urology</i> , 1997 , 157, 223-227	2.5	46
109	Investigation of germline PTEN, p53, p16(INK4A)/p14(ARF), and CDK4 alterations in familial glioma. <i>American Journal of Medical Genetics Part A</i> , 2000 , 92, 136-41		46
108	Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI. <i>American Journal of Neuroradiology</i> , 2017 , 38, 678-684	4.4	45
107	Prognostic value of cytogenetic analysis in human cerebral astrocytomas. <i>Annals of Neurology</i> , 1992 , 31, 534-42	9.4	45
106	Refractory thrombocytopenia. A myelodysplastic syndrome that may mimic immune thrombocytopenic purpura. <i>American Journal of Clinical Pathology</i> , 1992 , 98, 502-10	1.9	43
105	Understanding inherited genetic risk of adult glioma - a review. <i>Neuro-Oncology Practice</i> , 2016 , 3, 10-16	2.2	42
104	Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. <i>Oncotarget</i> , 2017 , 8, 27145-27154	3.3	40
103	Effective intravenous therapy for neurodegenerative disease with a therapeutic enzyme and a peptide that mediates delivery to the brain. <i>Molecular Therapy</i> , 2014 , 22, 547-553	11.7	39
102	Copy number variant analysis using genome-wide mate-pair sequencing. <i>Genes Chromosomes and Cancer</i> , 2018 , 57, 459-470	5	38
101	Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. <i>Oncotarget</i> , 2017 , 8, 18949-18967	3.3	38
100	Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis. <i>Neuro-Oncology</i> , 2013 , 15, 1041-7	1	36
99	Familial chordoma with probable autosomal dominant inheritance. <i>American Journal of Medical Genetics Part A</i> , 1998 , 75, 335-6		36
98	PPP6R3-USP6 amplification: Novel oncogenic mechanism in malignant nodular fasciitis. <i>Genes Chromosomes and Cancer</i> , 2016 , 55, 640-9	5	33
97	A novel region of deletion on chromosome 6q23.3 spanning less than 500 Kb in high grade invasive epithelial ovarian cancer. <i>Oncogene</i> , 1999 , 18, 3913-8	9.2	31
96	A Heritable Missense Polymorphism in CDKN2A Confers Strong Risk of Childhood Acute Lymphoblastic Leukemia and Is Preferentially Selected during Clonal Evolution. <i>Cancer Research</i> , 2015 , 75, 4884-94	10.1	30

95	Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21. <i>Scientific Reports</i> , 2018 , 8, 7352	4.9	30
94	Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential. <i>Journal of Urology</i> , 2017 , 197, 122-128	2.5	29
93	Development and Verification of an RNA Sequencing (RNA-Seq) Assay for the Detection of Gene Fusions in Tumors. <i>Journal of Molecular Diagnostics</i> , 2018 , 20, 495-511	5.1	28
92	Frequent homozygous deletions in the FRA3B region in tumor cell lines still leave the FHIT exons intact. <i>Oncogene</i> , 1998 , 16, 635-42	9.2	28
91	Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population. <i>Genetic Testing and Molecular Biomarkers</i> , 2001 , 5, 101-6		28
90	Frequent deletions within FRA7G at 7q31.2 in invasive epithelial ovarian cancer 1999 , 24, 48-55		28
89	Impact of atopy on risk of glioma: a Mendelian randomisation study. <i>BMC Medicine</i> , 2018 , 16, 42	11.4	27
88	Molecular profiling of long-term IDH-wildtype glioblastoma survivors. <i>Neuro-Oncology</i> , 2019 , 21, 1458-1469		27
87	Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer's disease brain. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019 , 16, 258-266	6	27
86	Mutation and expression analysis of the p73 gene in prostate cancer. <i>Prostate</i> , 1999 , 39, 94-100	4.2	26
85	Spinal Cord Ependymomas With MYCN Amplification Show Aggressive Clinical Behavior. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019 , 78, 791-797	3.1	25
84	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. <i>Neuro-Oncology</i> , 2019 , 21, 1498-1508	1	25
83	Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells. <i>Acta Neuropathologica</i> , 2001 , 101, 605-15	14.3	24
82	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. <i>Lancet Oncology, The</i> , 2021 , 22, 813-823	21.7	24
81	Impact of RNA degradation on fusion detection by RNA-seq. <i>BMC Genomics</i> , 2016 , 17, 814	4.5	24
80	History of chickenpox in glioma risk: a report from the glioma international case-control study (GICC). <i>Cancer Medicine</i> , 2016 , 5, 1352-8	4.8	23
79	Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2019 , 102, 87-96	3.8	23
78	Influence of obesity-related risk factors in the aetiology of glioma. <i>British Journal of Cancer</i> , 2018 , 118, 1020-1027	8.7	22

77	Peptide carrier-mediated non-covalent delivery of unmodified cisplatin, methotrexate and other agents via intravenous route to the brain. <i>PLoS ONE</i> , 2014 , 9, e97655	3.7	21
76	Genetic alterations and chemotherapeutic response in human diffuse gliomas. <i>Expert Review of Anticancer Therapy</i> , 2001 , 1, 595-605	3.5	21
75	Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e299-e309 ²⁰	3.3	20
74	Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case-control study. <i>Journal of Neurology</i> , 2018 , 265, 1432-1442	5.5	19
73	Sex-specific gene and pathway modeling of inherited glioma risk. <i>Neuro-Oncology</i> , 2019 , 21, 71-82	1	19
72	Detection of trisomy 12 by FISH in untreated B-chronic lymphocytic leukemia: correlation with stage and CD20 antigen expression intensity. <i>Leukemia and Lymphoma</i> , 1994 , 14, 447-51	1.9	19
71	Plenty of calcification: imaging characterization of polymorphous low-grade neuroepithelial tumor of the young. <i>Neuroradiology</i> , 2019 , 61, 1327-1332	3.2	18
70	CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. <i>Neuro-Oncology</i> , 2021 , 23, 457-467	1	18
69	Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors. <i>Cancer Research</i> , 2019 , 79, 905-917	10.1	17
68	Application of fluorescent in situ hybridization with X and Y chromosome specific probes to buccal smear analysis. <i>American Journal of Medical Genetics Part A</i> , 1996 , 66, 187-92		17
67	RNA sequencing identifies a novel USP9X-USP6 promoter swap gene fusion in a primary aneurysmal bone cyst. <i>Genes Chromosomes and Cancer</i> , 2019 , 58, 589-594	5	16
66	Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for Glioma. <i>Cancer Research</i> , 2019 , 79, 2065-2071	10.1	16
65	Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. <i>BJU International</i> , 2015 , 116, 556-67	5.6	14
64	Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics. <i>International Journal of Cancer</i> , 2020 , 146, 739-748	7.5	14
63	AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth. <i>Prostate</i> , 2016 , 76, 597-608	4.2	13
62	Age-specific genome-wide association study in glioblastoma identifies increased proportion of 'lower grade glioma'-like features associated with younger age. <i>International Journal of Cancer</i> , 2018 , 143, 2359-2366	7.5	13
61	Lack of association between modifiable exposures and glioma risk: a Mendelian randomization analysis. <i>Neuro-Oncology</i> , 2020 , 22, 207-215	1	12
60	Mendelian randomisation study of the relationship between vitamin D and risk of glioma. <i>Scientific Reports</i> , 2018 , 8, 2339	4.9	12

59	Uniparental disomy in congenital disorders: a prospective study. <i>American Journal of Medical Genetics Part A</i> , 1995 , 58, 143-6		12
58	Desmoplastic Infantile Ganglioglioma: A MAPK Pathway-Driven and Microglia/Macrophage-Rich Neuroepithelial Tumor. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019 , 78, 1011-1021	3.1	11
57	Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. <i>Genes Chromosomes and Cancer</i> , 2000 , 29, 16-25	5	11
56	Aspirin, NSAIDs, and Glioma Risk: Original Data from the Glioma International Case-Control Study and a Meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019 , 28, 555-562	4	11
55	Statistical considerations on prognostic models for glioma. <i>Neuro-Oncology</i> , 2016 , 18, 609-23	1	10
54	Generative Adversarial Networks to Synthesize Missing T1 and FLAIR MRI Sequences for Use in a Multisequence Brain Tumor Segmentation Model. <i>Radiology</i> , 2021 , 299, 313-323	20.5	10
53	Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2018 , 24, 3908-3916	12.9	10
52	Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis. <i>PLoS ONE</i> , 2015 , 10, e0116866	3.7	9
51	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. <i>Acta Neuropathologica</i> , 2021 , 141, 945-957	14.3	9
50	RNA-Seq Reveals Differences in Expressed Tumor Mutation Burden in Colorectal and Endometrial Cancers with and without Defective DNA-Mismatch Repair. <i>Journal of Molecular Diagnostics</i> , 2021 , 23, 555-564	5.1	9
49	Using germline variants to estimate glioma and subtype risks. <i>Neuro-Oncology</i> , 2019 , 21, 451-461	1	8
48	Biology and grading of pleomorphic xanthoastrocytoma-what have we learned about it?. <i>Brain Pathology</i> , 2021 , 31, 20-32	6	8
47	High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2015 , 18, 229-36	6.2	7
46	Restoration of epigenetically silenced SULF1 expression by 5-aza-2-deoxycytidine sensitizes hepatocellular carcinoma cells to chemotherapy-induced apoptosis. <i>Medical Epigenetics</i> , 2015 , 3, 1-18		7
45	HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 567-567	2.2	7
44	Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma. <i>Neuro-Oncology</i> , 2020 , 22, 1742-1756	1	7
43	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. <i>Neuro-Oncology</i> , 2021 , 23, 1547-1559	1	7
42	Novel BRAF alteration in desmoplastic infantile ganglioglioma with response to targeted therapy. <i>Acta Neuropathologica Communications</i> , 2018 , 6, 118	7.3	7

41	Improved Drug Delivery to Brain Metastases by Peptide-Mediated Permeabilization of the Blood-Brain Barrier. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 2171-2181	6.1	6
40	Molecular subtyping of tumors from patients with familial glioma. <i>Neuro-Oncology</i> , 2018 , 20, 810-817	1	6
39	A four-gene transcript score to predict metastatic-lethal progression in men treated for localized prostate cancer: Development and validation studies. <i>Prostate</i> , 2019 , 79, 1589-1596	4.2	6
38	Focal HER2/neu amplified clones partially account for discordance between immunohistochemistry and fluorescence in-situ hybridization results: data from NCCTG N9831 Intergroup Adjuvant Trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 568-568	2.2	6
37	Frequency of false-positive FISH 1p/19q codeletion in adult diffuse astrocytic gliomas. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdaa109	0.9	6
36	Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality. <i>BJU International</i> , 2017 , 119, 961-967	5.6	5
35	Adult diffuse glioma GWAS by molecular subtype identifies variants in D2HGDH and FAM20C. <i>Neuro-Oncology</i> , 2020 , 22, 1602-1613	1	5
34	Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018 , 27, 1376-1383	4	5
33	Loss of markers linked to BRCA1 precedes loss at important cell cycle regulatory genes in epithelial ovarian cancer. <i>Genes Chromosomes and Cancer</i> , 1999 , 25, 65-9	5	5
32	NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM). <i>Journal of Clinical Oncology</i> , 2004 , 22, 1503-1503	2.2	5
31	IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2 Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831. <i>Clinical Cancer Research</i> , 2017 , 23, 4203-4211	12.9	4
30	N997B: Phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM): Updated results and correlative laboratory analysis. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1505-1505	2.2	4
29	Functional analysis of low-grade glioma genetic variants predicts key target genes and transcription factors. <i>Neuro-Oncology</i> , 2021 , 23, 638-649	1	4
28	Giant Cell Ependymoma of Lateral Ventricle: Case Report, Literature Review, and Analysis of Prognostic Factors and Genetic Profile. <i>World Neurosurgery</i> , 2017 , 108, 997.e9-997.e14	2.1	3
27	Concomitant 1p/19q co-deletion and IDH1/2, ATRX, and TP53 mutations within a single clone of "dual-genotype" IDH-mutant infiltrating gliomas. <i>Acta Neuropathologica</i> , 2020 , 139, 1105-1107	14.3	3
26	Frequency of Clonal Evolution by FISH in Untreated, Early Stage Patients with CLL: A Prospective, Longitudinal Study with Long Clinical Follow-Up.. <i>Blood</i> , 2005 , 106, 2098-2098	2.2	3
25	Synchronous gemistocytic astrocytoma IDH-mutant and oligodendroglioma IDH-mutant and 1p/19q-codeleted in a patient with CCDC26 polymorphism. <i>Acta Neuropathologica</i> , 2017 , 134, 317-319	14.3	3
24	Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis. <i>Blood Cancer Journal</i> , 2021 , 11, 18	7	3

23	Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0M0 prostate cancer 1998 , 21, 131		3
22	The contribution of the rs55705857 G allele to familial cancer risk as estimated in the Utah population database. <i>BMC Cancer</i> , 2019 , 19, 190	4.8	2
21	Cytogenetic analysis of prostate carcinoma by fluorescence in situ hybridization. <i>International Journal of Urology</i> , 1995 , 2, 215-23	2.3	2
20	Immunohistochemical detection of EGFRvIII and prognostic significance in patients with malignant glioma enrolled in NCCTG clinical trials. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1508-1508	2.2	2
19	Immunohistochemical detection of EGFRvIII and prognostic significance in patients with malignant glioma enrolled in NCCTG clinical trials. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1508-1508	2.2	2
18	Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing. <i>Human Pathology</i> , 2021 , 112, 20-34	3.7	2
17	8q24 clear cell renal cell carcinoma germline variant is associated with VHL mutation status and clinical aggressiveness. <i>BMC Urology</i> , 2020 , 20, 173	2.2	1
16	OS06.1 Genome-wide association study reveals specific differences in genetic susceptibility to glioblastoma and non-glioblastoma. <i>Neuro-Oncology</i> , 2017 , 19, iii10-iii11	1	1
15	Gene Expression Correlates of Site-specific Metastasis Among Men With Lymph Node Positive Prostate Cancer Treated With Radical Prostatectomy: A Case Series. <i>Urology</i> , 2018 , 112, 29-32	1.6	1
14	Clinical and genomic analysis of metastatic disease progression in a background of biochemical recurrence.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 90-90	2.2	1
13	Missense SNP rs3731249 Explains the CDKN2A Association with Childhood ALL and Shows Risk Allele Selection in Tumors with Somatic CDKN2A Alterations. <i>Blood</i> , 2014 , 124, 129-129	2.2	1
12	Polymorphous Low-Grade Neuroepithelial Tumor of the Young (PLNTY): Molecular Profiling Confirms Frequent MAPK Pathway Activation. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021 , 80, 821-829	3.1	1
11	HER2 Testing for Breast Cancer in the Genomics Laboratory: A Sea Change for Fluorescence In Situ Hybridization. <i>Archives of Pathology and Laboratory Medicine</i> , 2021 , 145, 883-886	5	0
10	SeekFusion - A Clinically Validated Fusion Transcript Detection Pipeline for PCR-Based Next-Generation Sequencing of RNA. <i>Frontiers in Genetics</i> , 2021 , 12, 739054	4.5	0
9	N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020 , 182, 613-622	4.4	
8	Reply to Palacios et al., BRBB2 and MYC alterations in BRCA1- and BRCA2-associated cancers[] <i>Genes Chromosomes and Cancer</i> , 2005 , 42, 206-206	5	
7	Clinical Value of Next Generation Sequencing in the Detection of Recurring Structural Rearrangements and Copy Number Abnormalities in Acute Myeloid Leukemia. <i>Blood</i> , 2020 , 136, 21-22	2.2	
6	Validation of a genomic-clinical classifier for predicting clinical progression in high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4565-4565	2.2	

- 5 Development and validation of a digital Gleason score biomarker signature for risk stratification of patients with prostate cancer.. *Journal of Clinical Oncology*, **2012**, 30, 40-40 2.2
- 4 Validation of a genomic classifier that predicts metastatic disease progression in men with high-risk pathologic features postprostatectomy.. *Journal of Clinical Oncology*, **2013**, 31, 36-36 2.2
- 3 Chromosome 8 alterations and PTEN loss in Gleason grade 3 tumor to predict the presence of unsampled grade 4 tumor: Implications for active surveillance.. *Journal of Clinical Oncology*, **2014**, 32, 93-93 2.2
- 2 Detailed Reanalysis of 500 Breast Cancers With Equivocal HER2 Immunohistochemistry and Borderline ERBB2 Fluorescence In Situ Hybridization Results. *American Journal of Clinical Pathology*, **2021**, 156, 886-894 1.9
- 1 Non-canonical IDH Mutation Frequency in IDH1-R132H-Negative Glioblastoma Patients Older Than 54 Years. *Journal of Neuropathology and Experimental Neurology*, **2021**, 80, 804-806 3.1